{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:53:32Z","timestamp":1793141612200,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The evolving paradigm of continuous therapy and maintenance treatment approaches in multiple myeloma (MM) offers prolonged disease control and improved outcomes compared to traditional fixed-duration approaches. Potential benefits of long-term strategies include sustained control of disease symptoms, as well as continued cytoreduction and clonal control, leading to unmeasurable residual disease and the possibility of transforming MM into a chronic or functionally curable condition. \u201cContinuous therapy\u201d commonly refers to administering a doublet or triplet regimen until disease progression, whereas maintenance approaches typically involve single-agent or doublet treatment following more intensive prior therapy with autologous stem cell transplant (ASCT) or doublet, triplet, or even quadruplet induction therapy. However, the requirements for agents and regimens within these contexts are similar: treatments must be tolerable for a prolonged period of time, should not be associated with cumulative or chronic toxicity, should not adversely affect patients\u2019 quality of life, should ideally be convenient with a minimal treatment burden for patients, and should not impact the feasibility or efficacy of subsequent treatment at relapse. Multiple agents have been and are being investigated as long-term options in the treatment of newly diagnosed MM (NDMM), including the immunomodulatory drugs lenalidomide and thalidomide, the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, and the monoclonal antibodies daratumumab, elotuzumab, and isatuximab. Here we review the latest results with long-term therapy approaches in three different settings in NDMM: (1) maintenance treatment post ASCT; (2) continuous frontline therapy in nontransplant patients; (3) maintenance treatment post-frontline therapy in the nontransplant setting. We also discuss evidence from key phase 3 trials. Our review demonstrates how the paradigm of long-term treatment is increasingly well-established across NDMM treatment settings, potentially resulting in further improvements in patient outcomes, and highlights key clinical issues that will need to be addressed in order to provide optimal benefit.<\/jats:p>","DOI":"10.1038\/s41408-020-0273-x","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T14:04:05Z","timestamp":1581602645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"10","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S. Y.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8229-7439","authenticated-orcid":false,"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Skacel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Labotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"273_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3324\/haematol.2017.174573","volume":"103","author":"F Gay","year":"2018","unstructured":"Gay, F. et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 103, 197\u2013211 (2018).","journal-title":"Haematologica"},{"key":"273_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/asheducation-2017.1.212","volume":"2017","author":"H Ludwig","year":"2017","unstructured":"Ludwig, H. & Zojer, N. Fixed duration vs continuous therapy in multiple myeloma. Hematology Am. Soc. Hematol. Educ. Program 2017, 212\u2013222 (2017).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"273_CR3","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 33, 3459\u20133466 (2015).","journal-title":"J. Clin. Oncol."},{"key":"273_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon, T. et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131, 301\u2013310 (2018).","journal-title":"Blood"},{"key":"273_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1634\/theoncologist.2017-0440","volume":"23","author":"ED Pulte","year":"2018","unstructured":"Pulte, E. D. et al. FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist 23, 734\u2013739 (2018).","journal-title":"Oncologist"},{"key":"273_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","volume":"16","author":"SK Kumar","year":"2018","unstructured":"Kumar, S. K. et al. NCCN guidelines insights: multiple myeloma, version 3.2018. J. Natl. Compr. Canc. Netw. 16, 11\u201320 (2018).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"273_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","volume":"54","author":"WI Gonsalves","year":"2019","unstructured":"Gonsalves, W. I. et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 54, 353\u2013367 (2019).","journal-title":"Bone Marrow Transplant."},{"key":"273_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J. Clin. Oncol. 32, 587\u2013600 (2014).","journal-title":"J. Clin. Oncol."},{"key":"273_CR9","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"issue":"suppl_4","key":"273_CR10","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau, P. et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(suppl_4), iv52\u2013iv61 (2017).","journal-title":"Ann. Oncol."},{"key":"273_CR11","unstructured":"Kantar Health. Treatment Architecture: United States, Multiple Myeloma - CancerMPact\u00ae (Kantar Health, United States, 2017)."},{"key":"273_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab, M. S. et al. Multiple myeloma: practice patterns across Europe. Br. J. Haematol. 175, 66\u201376 (2016).","journal-title":"Br. J. Haematol."},{"key":"273_CR13","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/1078-0432.CCR-16-2895","volume":"23","author":"KC Anderson","year":"2017","unstructured":"Anderson, K. C. et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin. Cancer Res. 23, 3980\u20133993 (2017).","journal-title":"Clin. Cancer Res."},{"key":"273_CR14","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","volume":"12","author":"T Wilke","year":"2018","unstructured":"Wilke, T. et al. Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Prefer. Adherence 12, 2387\u20132396 (2018).","journal-title":"Patient Prefer. Adherence"},{"key":"273_CR15","doi-asserted-by":"publisher","first-page":"A454 (abstract)","DOI":"10.1016\/j.jval.2017.08.315","volume":"20","author":"D Romanus","year":"2017","unstructured":"Romanus, D. et al. Treatment satisfaction and burden of illness with oral vs injectable multiple myeloma therapy in patients with newly diagnosed disease (NDMM). Value Health 20, A454 (abstract) (2017).","journal-title":"Value Health"},{"key":"273_CR16","first-page":"1019","volume":"24","author":"D Merola","year":"2018","unstructured":"Merola, D., Yong, C., Noga, S. J. & Shermock, K. M. Costs associated with productivity loss among U.S. patients newly diagnosed with multiple myeloma receiving oral versus injectable chemotherapy. J. Manag. Care Spec. Pharm. 24, 1019\u20131026 (2018).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"S1","key":"273_CR17","first-page":"1001 (abstract","volume":"2","author":"WJ Chng","year":"2018","unstructured":"Chng, W. J. et al. Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM): current treatment landscape and emerging therapeutic options. Hemasphere 2(S1), 1001 (abstract PB2252) (2018).","journal-title":"Hemasphere"},{"key":"273_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrc3257","volume":"12","author":"GJ Morgan","year":"2012","unstructured":"Morgan, G. J., Walker, B. A. & Davies, F. E. The genetic architecture of multiple myeloma. Nat. Rev. Cancer 12, 335\u2013348 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"273_CR19","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","volume":"35","author":"JJ Lahuerta","year":"2017","unstructured":"Lahuerta, J. J. et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials. J. Clin. Oncol. 35, 2900\u20132910 (2017).","journal-title":"J. Clin. Oncol."},{"key":"273_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/cam4.1283","volume":"7","author":"N Lehners","year":"2018","unstructured":"Lehners, N. et al. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response. Cancer Med. 7, 307\u2013316 (2018).","journal-title":"Cancer Med."},{"issue":"Suppl 1","key":"273_CR21","first-page":"3098 (abstract)","volume":"130","author":"RA Fern\u00e1ndez","year":"2017","unstructured":"Fern\u00e1ndez, R. A. et al. Maintenance treatment with lenalidomide for multiple myeloma increases the proportion of MRD negative (Flow-\/PET-CT-) patients. Blood 130(Suppl 1), 3098 (abstract) (2017).","journal-title":"Blood"},{"key":"273_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos, M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 378, 518\u2013528 (2018).","journal-title":"N. Engl. J. Med."},{"key":"273_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","volume":"124","author":"MV Mateos","year":"2014","unstructured":"Mateos, M. V. et al. GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 124, 1887\u20131893 (2014).","journal-title":"Blood"},{"key":"273_CR24","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/cncr.31854","volume":"125","author":"M Gambella","year":"2019","unstructured":"Gambella, M. et al. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis. Cancer 125, 750\u2013760 (2019).","journal-title":"Cancer"},{"issue":"Suppl 1","key":"273_CR25","first-page":"436 (abstract)","volume":"130","author":"G Jackson","year":"2017","unstructured":"Jackson, G. et al. Lenalidomide maintenance significantly improves outcomes compared to observation irrespective of cytogenetic risk: results of the Myeloma XI Trial. Blood 130(Suppl 1), 436 (abstract) (2017).","journal-title":"Blood"},{"key":"273_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","volume":"119","author":"GJ Morgan","year":"2012","unstructured":"Morgan, G. J. et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119, 7\u201315 (2012).","journal-title":"Blood"},{"key":"273_CR27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","volume":"115","author":"HM Lokhorst","year":"2010","unstructured":"Lokhorst, H. M. et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115, 1113\u20131120 (2010).","journal-title":"Blood"},{"key":"273_CR28","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","volume":"121","author":"AK Stewart","year":"2013","unstructured":"Stewart, A. K. et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 121, 1517\u20131523 (2013).","journal-title":"Blood"},{"key":"273_CR29","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1016\/S2352-3026(18)30149-2","volume":"5","author":"NW van de Donk","year":"2018","unstructured":"van de Donk, N. W. et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 5, e479\u2013e492 (2018).","journal-title":"Lancet Haematol."},{"key":"273_CR30","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","volume":"119","author":"H Ludwig","year":"2012","unstructured":"Ludwig, H. et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 119, 3003\u20133015 (2012).","journal-title":"Blood"},{"key":"273_CR31","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan, G. J. et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin. Cancer Res. 19, 6030\u20136038 (2013).","journal-title":"Clin. Cancer Res."},{"key":"273_CR32","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J. Clin. Oncol. 35, 3279\u20133289 (2017).","journal-title":"J. Clin. Oncol."},{"key":"273_CR33","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","volume":"4","author":"SA Holstein","year":"2017","unstructured":"Holstein, S. A. et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 4, e431\u2013e442 (2017).","journal-title":"Lancet Haematol."},{"key":"273_CR34","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","volume":"366","author":"PL McCarthy","year":"2012","unstructured":"McCarthy, P. L. et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1770\u20131781 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"273_CR35","doi-asserted-by":"publisher","first-page":"4737 (abstract)","DOI":"10.1182\/blood-2018-99-113001","volume":"132","author":"PL McCarthy","year":"2018","unstructured":"McCarthy, P. L. et al. Survival analysis from the CALGB study of lenalidomide maintenance therapy in newly diagnosed multiple myeloma post-autologous stem cell transplantation adjusted for crossover (Alliance 100104). Blood 132(Suppl 1), 4737 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR36","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","volume":"366","author":"M Attal","year":"2012","unstructured":"Attal, M. et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366, 1782\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"273_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. N. Engl. J. Med. 371, 895\u2013905 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"273_CR38","doi-asserted-by":"publisher","first-page":"5643 (abstract)","DOI":"10.1182\/blood-2018-99-117705","volume":"132","author":"H Cherniawsky","year":"2018","unstructured":"Cherniawsky, H. et al. Lenalidomide maintenance does not negatively impact overall and progression free survival using lenalidomide-based regimens for multiple myeloma in first relapse. Blood 132(Suppl 1), 5643 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR39","doi-asserted-by":"publisher","first-page":"3232 (abstract)","DOI":"10.1182\/blood-2018-99-110877","volume":"132","author":"S Jagannath","year":"2018","unstructured":"Jagannath, S. et al. Treatment choices and outcomes for patients with multiple myeloma after relapse on lenalidomide maintenance therapy: results from the Connect MM Registry. Blood 132(Suppl 1), 3232 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson, G. H. et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 20, 57\u201373 (2019).","journal-title":"Lancet Oncol."},{"key":"273_CR41","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","volume":"16","author":"F Gay","year":"2015","unstructured":"Gay, F. et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 16, 1617\u20131629 (2015).","journal-title":"Lancet Oncol."},{"key":"273_CR42","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal, M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N. Engl. J. Med. 376, 1311\u20131320 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"273_CR43","doi-asserted-by":"publisher","first-page":"1982 (abstract)","DOI":"10.1182\/blood-2018-99-116464","volume":"132","author":"SK Thomas","year":"2018","unstructured":"Thomas, S. K. et al. Updated results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous stem cell transplant (AuSCT) in patients (Pts) with multiple myeloma (MM). Blood 132(Suppl 1), 1982 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR44","doi-asserted-by":"crossref","first-page":"904 (abstract)","DOI":"10.1182\/blood.V130.Suppl_1.904.904","volume":"130","author":"RM de Tute","year":"2017","unstructured":"de Tute, R. M. et al. Minimal residual disease in the maintenance setting in myeloma: prognostic significance and impact of lenalidomide. Blood 130(Suppl 1), 904 (abstract) (2017).","journal-title":"Blood"},{"key":"273_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","volume":"106","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos, M. A. et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur. J. Cancer 106, 89\u201398 (2019).","journal-title":"Eur. J. Cancer"},{"key":"273_CR46","doi-asserted-by":"crossref","unstructured":"Oliva, S. et al. Minimal residual disease (MRD) by multiparameter flow cytometry (MFC) in transplant eligible patients with newly diagnosed multiple myeloma (MM): results from the EMN02\/HO95 phase 3 trial. Haematologica 102(s2), 2 (abstract S102) (2017).","DOI":"10.1200\/JCO.2017.35.15_suppl.8011"},{"key":"273_CR47","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","volume":"2","author":"S Jagannath","year":"2018","unstructured":"Jagannath, S. et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2, 1608\u20131615 (2018).","journal-title":"Blood Adv."},{"key":"273_CR48","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.clinthera.2018.05.017","volume":"40","author":"RM Rifkin","year":"2018","unstructured":"Rifkin, R. M. et al. Treatment outcomes and health care resource utilization in patients with newly diagnosed multiple myeloma receiving lenalidomide-only maintenance, any maintenance, or no maintenance: results from the Connect MM Registry. Clin. Ther. 40, 1193\u20131202 e1191 (2018).","journal-title":"Clin. Ther."},{"key":"273_CR49","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","volume":"97","author":"R Abonour","year":"2018","unstructured":"Abonour, R. et al. Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect(R) MM Registry. Ann. Hematol. 97, 2425\u20132436 (2018).","journal-title":"Ann. Hematol."},{"key":"273_CR50","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/leu.2017.256","volume":"32","author":"R Chakraborty","year":"2018","unstructured":"Chakraborty, R. et al. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. Leukemia 32, 712\u2013718 (2018).","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"273_CR51","first-page":"3462 (abstract)","volume":"130","author":"C Yang","year":"2017","unstructured":"Yang, C. et al. Tolerability and efficacy of post transplant lenalidomide maintenance therapy in multiple myeloma: a real world single centre experience. Blood 130(Suppl 1), 3462 (abstract) (2017).","journal-title":"Blood"},{"key":"273_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/leu.2017.211","volume":"32","author":"H Goldschmidt","year":"2018","unstructured":"Goldschmidt, H. et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial. Leukemia 32, 383\u2013390 (2018).","journal-title":"Leukemia"},{"key":"273_CR53","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld, P. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/ GMMG-HD4 trial. J. Clin. Oncol. 30, 2946\u20132955 (2012).","journal-title":"J. Clin. Oncol."},{"key":"273_CR54","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2017.35","volume":"31","author":"L Rosinol","year":"2017","unstructured":"Rosinol, L. et al. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial. Leukemia 31, 1922\u20131927 (2017).","journal-title":"Leukemia"},{"key":"273_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2017013334","volume":"2","author":"M Merz","year":"2018","unstructured":"Merz, M. et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv. 2, 1\u20139 (2018).","journal-title":"Blood Adv."},{"key":"273_CR56","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/leu.2013.335","volume":"28","author":"AK Nooka","year":"2014","unstructured":"Nooka, A. K. et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28, 690\u2013693 (2014).","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"273_CR57","doi-asserted-by":"publisher","first-page":"2153 (abstract)","DOI":"10.1182\/blood-2018-99-118443","volume":"132","author":"K Nadiminti","year":"2018","unstructured":"Nadiminti, K. et al. A single autologous stem cell transplant (ASCT) followed by two years of post-transplant therapy in recently diagnosed elderly multiple myeloma (MM) patients. safety and response results from the prospective phase II trial (NCT01849783). Blood 132(Suppl 1), 2153 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR58","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393, 253\u2013264 (2018).","journal-title":"Lancet"},{"issue":"Suppl 1","key":"273_CR59","first-page":"437 (abstract)","volume":"130","author":"KK Patel","year":"2017","unstructured":"Patel, K. K. et al. Update on a phase II study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma. Blood 130(Suppl 1), 437 (abstract) (2017).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR60","first-page":"400 (abstract)","volume":"130","author":"H Goldschmidt","year":"2017","unstructured":"Goldschmidt, H. et al. Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial. Blood 130(Suppl 1), 400 (abstract) (2017).","journal-title":"Blood"},{"key":"273_CR61","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00432-018-2641-5","volume":"144","author":"C Cerrato","year":"2018","unstructured":"Cerrato, C. et al. Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. J. Cancer Res. Clin. Oncol. 144, 1357\u20131366 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"Suppl 1","key":"273_CR62","doi-asserted-by":"publisher","first-page":"3432 (abstract)","DOI":"10.1182\/blood-2018-99-112790","volume":"132","author":"MV Solovev","year":"2018","unstructured":"Solovev, M. V. et al. Efficacy of maintenance therapy following auto-HSCT depending on MRD status in patients with multiple myeloma. Blood 132(Suppl 1), 3432 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR63","doi-asserted-by":"publisher","first-page":"121 (abstract)","DOI":"10.1182\/blood-2018-99-112093","volume":"132","author":"F Gay","year":"2018","unstructured":"Gay, F. et al. Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-Krd consolidation vs KRd 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized forte trial in newly diagnosed multiple myeloma (NDMM). Blood 132(Suppl 1), 121 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR64","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906\u2013917 (2014).","journal-title":"N. Engl. J. Med."},{"key":"273_CR65","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/leu.2017.111","volume":"31","author":"NJ Bahlis","year":"2017","unstructured":"Bahlis, N. J. et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia 31, 2435\u20132442 (2017).","journal-title":"Leukemia"},{"key":"273_CR66","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3324\/haematol.2015.133629","volume":"101","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica 101, 363\u2013370 (2016).","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"273_CR67","doi-asserted-by":"publisher","first-page":"305 (abstract)","DOI":"10.1182\/blood-2018-99-111796","volume":"132","author":"A Larocca","year":"2018","unstructured":"Larocca, A. et al. Efficacy and feasibility of dose\/schedule-adjusted Rd-R vs. continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study. Blood 132(Suppl 1), 305 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR68","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"273_CR69","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie, B. G. et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"issue":"Suppl 1","key":"273_CR70","doi-asserted-by":"publisher","first-page":"1992 (abstract)","DOI":"10.1182\/blood-2018-99-117003","volume":"132","author":"BGM Durie","year":"2018","unstructured":"Durie, B. G. M. et al. Longer term follow up of the a randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood 132(Suppl 1), 1992 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR71","doi-asserted-by":"publisher","first-page":"4744 (abstract)","DOI":"10.1182\/blood-2018-99-112882","volume":"132","author":"K Ramasamy","year":"2018","unstructured":"Ramasamy, K., Thom, H., D\u2019Souza, V. K., Buchanan, V. & Dhanasiri, S. Relative efficacy of treatment options in newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Blood 132(Suppl 1), 4744 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR72","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo, A. et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N. Engl. J. Med. 366, 1759\u20131769 (2012).","journal-title":"N. Engl. J. Med."},{"key":"273_CR73","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","volume":"127","author":"S Zweegman","year":"2016","unstructured":"Zweegman, S. et al. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood 127, 1109\u20131116 (2016).","journal-title":"Blood"},{"key":"273_CR74","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","volume":"126","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood 126, 1294\u20131301 (2015).","journal-title":"Blood"},{"key":"273_CR75","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","volume":"127","author":"V Magarotto","year":"2016","unstructured":"Magarotto, V. et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood 127, 1102\u20131108 (2016).","journal-title":"Blood"},{"key":"273_CR76","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","volume":"120","author":"MV Mateos","year":"2012","unstructured":"Mateos, M. V. et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120, 2581\u20132588 (2012).","journal-title":"Blood"},{"key":"273_CR77","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo, A. et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28, 5101\u20135109 (2010).","journal-title":"J. Clin. Oncol."},{"key":"273_CR78","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Niesvizky","year":"2015","unstructured":"Niesvizky, R. et al. Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens. J. Clin. Oncol. 33, 3921\u20133929 (2015).","journal-title":"J. Clin. Oncol."},{"key":"273_CR79","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/leu.2017.327","volume":"32","author":"S Bringhen","year":"2018","unstructured":"Bringhen, S. et al. Phase 1\/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia 32, 979\u2013985 (2018).","journal-title":"Leukemia"},{"key":"273_CR80","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 15, 1503\u20131512 (2014).","journal-title":"Lancet Oncol."},{"key":"273_CR81","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjh.15394","volume":"182","author":"PG Richardson","year":"2018","unstructured":"Richardson, P. G. et al. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br. J. Haematol. 182, 231\u2013244 (2018).","journal-title":"Br. J. Haematol."},{"key":"273_CR82","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3324\/haematol.2017.185991","volume":"103","author":"JF San-Miguel","year":"2018","unstructured":"San-Miguel, J. F. et al. A phase I\/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica 103, 1518\u20131526 (2018).","journal-title":"Haematologica"},{"issue":"7","key":"273_CR83","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","volume":"33","author":"Shaji K. Kumar","year":"2019","unstructured":"Kumar, S. K. et al. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia 33, 1736\u20131746 (2019).","journal-title":"Leukemia"},{"key":"273_CR84","doi-asserted-by":"crossref","unstructured":"Dimopoulos, M. A. et al. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I\/II studies. Eur J Haematol 102, 494\u2013503 (2019).","DOI":"10.1111\/ejh.13231"},{"issue":"Suppl 1","key":"273_CR85","doi-asserted-by":"publisher","first-page":"596 (abstract)","DOI":"10.1182\/blood-2018-99-114668","volume":"132","author":"CAM Stege","year":"2018","unstructured":"Stege, C. A. M. et al. Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) in unfit and frail newly diagnosed multiple myeloma (NDMM) patients; first interim safety analysis of the phase II HOVON 143 study. Blood 132(Suppl 1), 596 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR86","doi-asserted-by":"publisher","first-page":"800 (abstract)","DOI":"10.1182\/blood-2018-99-111650","volume":"132","author":"S Zweegman","year":"2018","unstructured":"Zweegman, S. et al. Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126\/Nmsg 21#13 trial. Blood 132(Suppl 1), 800 (abstract) (2018).","journal-title":"Blood"},{"issue":"Supplement 1","key":"273_CR87","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2018-156","volume":"132","author":"Meletios A Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. One-year update of a phase 3 randomized study of daratumumab plus bortezomib, melphalan, and prednisone (DVMP) versus bortezomib, melphalan, and prednisone (VMP) in patients (Pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): Alcyone. Blood 132(Suppl 1), 156 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR88","doi-asserted-by":"publisher","first-page":"4741 (abstract)","DOI":"10.1182\/blood-2018-99-113668","volume":"132","author":"JF San-Miguel","year":"2018","unstructured":"San-Miguel, J. F. et al. Treatment regimens for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: a systematic literature review and network meta-analysis. Blood 132(Suppl 1), 4741 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR89","doi-asserted-by":"publisher","first-page":"3551 (abstract)","DOI":"10.1182\/blood-2018-99-113517","volume":"132","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. A matching-adjusted indirect treatment comparison of daratumumab-bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone continuous, lenalidomide-dexamethasone 18 months, and melphalan-prednisone-thalidomide. Blood 132(Suppl 1), 3551 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR90","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41409-018-0177-6","volume":"53","author":"J Huang","year":"2018","unstructured":"Huang, J. et al. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant. 53, 701\u2013707 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"273_CR91","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/s41375-018-0040-1","volume":"32","author":"H Ludwig","year":"2018","unstructured":"Ludwig, H. et al. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 32, 1542\u20131560 (2018).","journal-title":"Leukemia"},{"key":"273_CR92","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15459","volume":"182","author":"KL Royle","year":"2018","unstructured":"Royle, K. L. et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br. J. Haematol. 182, 816\u2013829 (2018).","journal-title":"Br. J. Haematol."},{"key":"273_CR93","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3324\/haematol.2014.120121","volume":"100","author":"M Delforge","year":"2015","unstructured":"Delforge, M. et al. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica 100, 826\u2013833 (2015).","journal-title":"Haematologica"},{"key":"273_CR94","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/10428194.2017.1334125","volume":"59","author":"DT Vogl","year":"2018","unstructured":"Vogl, D. T. et al. Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. Leuk. Lymphoma 59, 398\u2013405 (2018).","journal-title":"Leuk. Lymphoma"},{"issue":"Suppl 1","key":"273_CR95","doi-asserted-by":"publisher","first-page":"2003 (abstract)","DOI":"10.1182\/blood-2018-99-110977","volume":"132","author":"A Boquoi","year":"2018","unstructured":"Boquoi, A. et al. Similar quality of life with 5mg versus 25mg lenalidomide maintenance after first-line high-dose therapy and autologous blood stem cell transplantation for multiple myeloma: results of the Lenamain trial. Blood 132(Suppl 1), 2003 (abstract) (2018).","journal-title":"Blood"},{"key":"273_CR96","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","volume":"23","author":"R Baz","year":"2015","unstructured":"Baz, R. et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer 23, 2789\u20132797 (2015).","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"273_CR97","first-page":"5407 (abstract)","volume":"130","author":"RM Rifkin","year":"2017","unstructured":"Rifkin, R. M. et al. Tourmaline US-MM6, an open-label, single-arm, multicenter study evaluating the effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) switching from a bortezomib-based triplet induction regimen. Blood 130(Suppl 1), 5407 (abstract) (2017).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR98","first-page":"3405 (abstract)","volume":"130","author":"G Jackson","year":"2017","unstructured":"Jackson, G., Dutton, R., Zamagni, E., Hughes, R. & Dhanasiri, S. Lenalidomide maintenance therapy post-autologous stem cell transplant: a healthcare cost-impact analysis in Europe. Blood 130(Suppl 1), 3405 (abstract) (2017).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR99","doi-asserted-by":"publisher","first-page":"3555 (abstract)","DOI":"10.1182\/blood-2018-99-112826","volume":"132","author":"CA Uyl-de Groot","year":"2018","unstructured":"Uyl-de Groot, C. A., Ramsden, R., Boersma, J., Zweegman, S. & Dhanasiri, S. Lenalidomide as maintenance treatment for patients with newly diagnosed multiple myeloma post-autologous stem cell transplantation: a pharmacoeconomic assessment in the Netherlands. Blood 132(Suppl 1), 3555 (abstract) (2018).","journal-title":"Blood"},{"issue":"Suppl 1","key":"273_CR100","doi-asserted-by":"publisher","first-page":"3535 (abstract)","DOI":"10.1182\/blood-2018-99-112942","volume":"132","author":"Z-Y Zhou","year":"2018","unstructured":"Zhou, Z.-Y. et al. Cost-effectiveness analysis of lenalidomide for maintenance therapy after autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) patients: a United States payer perspective. Blood 132(Suppl 1), 3535 (abstract) (2018).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0273-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0273-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0273-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:25:19Z","timestamp":1670232319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0273-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["273"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0273-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"13 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.D.: Genesis Pharma: Research Funding; Novartis: Consultancy, Honoraria; Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology: Consultancy, Honoraria, Other: Advisory Committee. A.J.J.: Consultant and Advisory Boards with honoraria for AbbVie, Amgen, BMS, Celgene, Janssen, Juno, Karyopharm, SkylineDx, Takeda. P.L.M.: honoraria from Celgene, Bristol-Myers Squibb, Sanofi, Takeda, The Binding Site, and Karyopharm Therapeutics; consulting or advisory role for Celgene, Janssen, Bristol-Myers Squibb, Sanofi, and Karyopharm Therapeutics; research funding from Celgene. RZO: research funding from BioTheryX; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Janssen, Millennium Pharmaceuticals, and Onyx Pharmaceuticals; member of advisory boards for Amgen, Bristol-Myers Squibb, Celgene Corporation, Incyte, Juno, Kite, Legend Biotech, Sanofi-Aventis, and Takeda Pharmaceuticals. M.A.: None. J.B.: honoraria from Janssen, Celgene, Amgen, and Takeda; grant support from Janssen and Celgene. H.G.: advisory boards for Adaptive Biotechnology, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, and Takeda; research funding from Amgen, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Sanofi, Mundipharma, Takeda, and Novartis; honoraria from ArtTempi, Bristol-Myers Squibb, Celgene, Chugai, Janssen, and Novartis. K.C.W.: Advisory boards for Amgen, Bristol-Myers Squibb, Adaptive Biotech, Celgene, Janssen, Juno, Takeda, Sanofi; honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; research funding from Amgen, Celgene, Janssen, and Sanofi. K.R.: Takeda: honoraria, research funding; Amgen: honoraria; Janssen: honoraria; Celgene: honoraria, research funding; Adaptive Biotech: Honoraria; Oncopeptides: Honoraria. S.Z.: research funding from and advisory boards for Takeda, Celgene, and Janssen. A.S.: consultancy for Specialised Therapeutics Australia; honoraria from Takeda, Celgene, Janssen, and Amgen; speaker bureaus for Takeda, Celgene, and Janssen; research funding from Takeda, Celgene, Janssen, and GlaxoSmithKline. J.S.Y.H.: honoraria and advisory boards for Takeda, Celgene, and Janssen. J.L.: None. K.S.: research funding from Takeda, MSD, Celgene, GSK, Novartis, Ono, Janssen, Abbvie, Sanofi, Bristol-Myers Squibb, Alexion-pharma, Diichi-Sankyo; honoraria from Takeda, Celgene, Ono, Bristol-Myers Squibb. S.I.: research funding from Takeda, Ono, Janssen, Celgene, Novartis, Chugai, Abbvie, Bristol-Myers Squibb, Kyowa-Hakko Kirin, Merck Sharp & Dohme, Daiichi Sankyo, Gilead; honoraria from Takeda, Janssen, Celgene, Ono, Daiichi Sankyo, and Bristol-Myers Squibb. W.-J.C.: honoraria from Takeda. S.A.H.: Consultant: Celgene, Sorrento, GSK; Advisory boards: Adaptive Biotechnologies, Takeda. A.R.: Consultancy for Sanofi and Takeda; honoraria from Janssen, Takeda, Celgene, Novartis, Amgen; Advisory board for Novartis, Janssen, Amgen. T.S., R.L., A.P.: Employment, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. T.S.: also affiliated with Department of Hematology, Charles University General Hospital, Prague, Czech Republic. K.C.A.: Membership on an entity\u2019s Board of Directors or advisory committees for Bristol-Myers Squibb, Gilead Sciences, Celgene, Janssen, Sanofi-Aventis, Millennium Pharmaceuticals; Scientific founder: Oncopep, C4 Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"17"}}